Erasca Stock Surges 42% in a Week: Here's What You Should Know

Shares of Erasca ERAS soared 41.5% in a week. The massive gain was observed after the company announced encouraging early clinical data from the phase I study of its investigational candidate, ERAS-0015, being developed for patients with RAS-mutant solid tumors.

Additionally, Erasca also announced updates from a separate early-stage study of another oncology candidate, ERAS-4001, along with its 2026-2027 milestones.

Erasca’s ERAS-0015 Study Initial Data in Detail

Per Erasca, ERAS-0015 is an oral, highly potent pan-RAS molecular glue that targets RAS signaling and has the potential to deliver a best-in-class therapeutic profile. The company reported that dose escalation in the ongoing phase I AURORAS-1 study of the candidate is progressing faster than originally anticipated, reflecting the significant unmet medical need in RAS-driven cancers as well as strong enthusiasm from investigators and patients. Enrollment momentum has supported rapid advancement through multiple dose levels.

Encouraging early efficacy signals have been observed across multiple tumor types and RAS mutations. At a low dose of 8 mg once daily, two confirmed partial responses and one unconfirmed partial response have been reported, with additional ongoing unconfirmed responses seen at higher dose levels.

In the past six months, shares of Erasca have skyrocketed 541.6% compared with the industry’s 23.2% growth.

ERAS-0015 has also demonstrated a favorable safety and tolerability profile to date. No dose-limiting toxicities have been observed, and adverse events have been predominantly low grade across all evaluated dose levels, supporting continued dose escalation and expansion.

Pharmacokinetic data indicate a well-behaved, linear profile across all tested doses, with no evidence of an exposure plateau as of the data cutoff date of Jan. 7, 2026. This supports predictable dosing and provides flexibility for future monotherapy and combination strategies.

Looking ahead, initial phase I ERAS-0015 monotherapy data in patients with RAS-mutant solid tumors are expected in the first half of 2026. Erasca plans to initiate monotherapy expansion cohorts and combination dose-escalation cohorts in the AURORAS-1 study in late 2026, with expansion and combination data anticipated in 2027.

Update on Erasca’s Other Pipeline Candidate

Apart from ERAS-0015, Erasca’s clinical-stage pipeline comprises another candidate currently undergoing phase I development for patients with KRAS-mutant solid tumors. Per the company, ERAS-4001 is an oral, highly potent and highly selective pan-KRAS inhibitor with the potential to deliver both first-in-class and best-in-class performance.

In the same press release, Erasca reported that dose escalation in the ongoing phase I BOREALIS-1 study of ERAS-4001 for KRAS-mutant solid tumors is progressing as planned, supporting the program’s development timeline.

Initial phase I ERAS-4001 monotherapy data in patients with KRAS-mutant solid tumors are expected in the second half of 2026, covering safety, tolerability, pharmacokinetics and early efficacy. The company also plans to initiate monotherapy expansion cohorts and combination dose-escalation cohorts in the BOREALIS-1 study in 2027.

Erasca, Inc. Price and Consensus

Erasca, Inc. price-consensus-chart | Erasca, Inc. Quote

ERAS’ Zacks Rank and Stocks to Consider

Erasca currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Amicus Therapeutics FOLD, Alkermes ALKS and Krystal Biotech KRYS, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Amicus Therapeutics’ 2026 EPS have decreased from 67 cents to 65 cents. Shares of FOLD have surged 127.6% over the past six months.

Amicus Therapeutics’ earnings beat estimates in one of the trailing four quarters, missing the mark on the other three occasions, delivering an average negative surprise of 20.21%.

Over the past 60 days, 2026 EPS estimates for Alkermes have increased from $1.54 to $1.80. Shares of ALKS have gained 6.3% over the past six months.

Alkermes’ earnings beat estimates in three of the trailing four quarters, missing on the remaining occasion, with the average surprise being 4.58%.

Over the past 60 days, estimates for Krystal Biotech’s EPS for 2026 have risen to $8.49 from $8.34. KRYS stock has rallied 87.8% over the past six months.

Krystal Biotech’s earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 40.43%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research